All In Biotech

Free tool

FAERS Monitor: Avgemsi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219920 or its brand name (Avgemsi, Gemcitabine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

40,140

Serious

38,987

97% of reports

Hospitalization

15,169

Death reported

7,548

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disease progression4,646
  • thrombocytopenia3,043
  • off label use2,910
  • drug ineffective2,705
  • neutropenia2,703
  • anaemia2,483
  • malignant neoplasm progression2,153
  • nausea2,032
  • pyrexia1,978
  • fatigue1,707
  • diarrhoea1,674
  • vomiting1,616
  • death1,543
  • febrile neutropenia1,407
  • dyspnoea1,226

Reports by year received

View as table
YearReports
2004486
2005473
2006521
2007344
2008418
2009591
2010452
2011571
2012885
2013800
20141,061
20151,994
20162,392
20172,252
20182,507
20192,656
20202,546
20212,586
20223,132
20234,004
20243,373
20253,434
20262,662

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,014,019 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
disease progressionSignal4,64621.420.887,158
thrombocytopeniaSignal3,04314.614.137,776
febrile neutropeniaSignal1,40711.310.813,006
malignant neoplasm progressionSignal2,15311.210.819,730
neutropeniaSignal2,70310.610.223,194
anaemiaSignal2,4836.96.612,467
pyrexiaSignal1,9783.02.92,676
vomiting1,6161.81.7589
off label use2,9101.71.7959
diarrhoea1,6741.41.3164
nausea2,0321.31.3187
fatigue1,7071.11.134
dyspnoea1,2261.11.120
drug ineffective2,7051.11.015
death1,5430.90.96

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.